Found 6 results
[ Author(Asc)] Title Type Year
Filters: Author is Ledgerwood, JE  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
L
J. E. Ledgerwood, Bellamy, A. R., Belshe, R., Bernstein, D. I., Edupuganti, S., Patel, S. M., Renehan, P., Zajdowicz, T., Schwartz, R., Koup, R., Bailer, R. T., Yamshchikov, G. V., Enama, M. E., Sarwar, U., Larkin, B., and Graham, B. S., DNA Priming for Seasonal Influenza Vaccine: a Phase 1b Double-Blind Randomized Clinical Trial, PLoS One, vol. 10, no. 5, p. e0125914, 2015.
J. E. Ledgerwood, Yamschikov, G., Enama, M. E., Sarwar, U. N., Bailer, R. T., Larkin, B., Bellamy, A. R., Anderson, E. L., Bernstein, D. I., Creech, B., Keyserling, H., Spearman, P., Wright, P., and Graham, B., VRC 702: A Multicenter Phase 1 Study of Seasonal Influenza DNA Vaccine Prime Followed by the Trivalent Inactivated Vaccine (TIV) Compared to TIV-TIV in Children and Adolescents Ages 6-17 Years, in 2014 Annual Conference on Vaccine Research, Bethesda, MD, 2014.
J. E. Ledgerwood, Zephir, K., Hu, Z., Wei, C. J., Chang, L., Enama, M. E., Hendel, C. S., Sitar, S., Bailer, R. T., Koup, R. A., ,, Nabel, G. J., and Graham, B. S., Prime-Boost Interval Matters: A Randomized Phase 1 Study to Identify the Minimum Interval Necessary to Observe the H5 DNA Influenza Vaccine Priming Effect, J Infect Dis, vol. 208, pp. 418-422, 2013.
J. E. Ledgerwood, Wei, C. J., Hu, Z., Gordon, I. J., Enama, M. E., Hendel, C. S., McTamney, P. M., Pearce, M. B., Yassine, H. M., Boyington, J. C., Bailer, R., Tumpey, T. M., Koup, R. A., ,, Nabel, G. J., and Graham, B. S., DNA Priming and Influenza Vaccine Immunogenicity: Two Phase 1 Open Label Randomised Clinical Trials, Lancet Infect Dis, vol. 11, no. 12, pp. 916-924, 2011.
J. E. Ledgerwood, Pierson, T. C., Hubka, S. A., Desai, N., Rucker, S., Gordon, I. J., Enama, M. E., Nelson, S., Nason, M., Gu, W., Bundrant, N., Koup, R. A., Bailer, R. T., ,, Nabel, G. J., and Graham, B. S., A West Nile Virus DNA Vaccine Utilizing a Modified Promoter Induces Neutralizing Antibody in Younger and Older Healthy Adults in a Phase I Clinical Trial, J Infect Dis, vol. 203, no. 10, pp. 1396-1404, 2011.
J. E. Ledgerwood, Costner, P., Desai, N., Holman, L., Enama, M. E., Yamshchikov, G., Mulangu, S., Hu, Z., Andrews, C. A., Sheets, R. A., Koup, R. A., Roederer, M., Bailer, R., ,, Pau, M. G., Sullivan, N. J., Goudsmit, J., Nabel, G. J., and Graham, B. S., A Replication Defective Recombinant Ad5 Vaccine Expressing Ebola Virus GP is Safe and Immunogenic in Healthy Adults, Vaccine, vol. 29, no. 2, pp. 304-313, 2010.